Intestinal Research

Original Article

IBD

Health-related quality of life, work productivity, and persisting challenges in treated ulcerative colitis patients: a Japanese National Health and Wellness Survey: Sakiko Hiraoka, Zhezhou Huang, Fei Qin, Fatima Megala Nathan Arokianathan, Kiran Davé, Shweta Shah, Hyunchung Kim; Intest Res 2025;23(4):524-540. Published online January 2, 2025; DOI: https://doi.org/10.5217/ir.2024.00104

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Despite available treatments for ulcerative colitis (UC), unmet needs persist among patients in Japan. This study explored the health-related quality of life (HRQoL), work productivity and activity impairment (WPAI), indirect cost, and unmet needs among treated UC patients in Japan.
Methods
This cross-sectional, observational study utilized data from the online 2017, 2019, and 2021 Japan National Health and Wellness Survey. Respondents were aged ≥ 18 years and had undergone or were on UC treatment (5-aminosalicylic acid, steroids, immunomodulators/immunosuppressants, biologics/Janus kinase inhibitors [JAKi]). Demographic, general health, and clinical characteristics, medication adherence, HRQoL, WPAI, and indirect cost were collected and analyzed.
Results
Among 293 treated UC patients, 83.6% were non-biologic/JAKi users, 29.0% had UC ≥ 15 years, 34.8% had moderate-to-severe disease severity, 55.3% experienced ≥ 1 persisting UC symptom, and 91.5% reported UC as bothersome to an extent. Patients reported EuroQoL visual analog scale score of 68.1 and ≥ 35% reported anxiety and depression. Mean work productivity loss was 29.3%, resulting in an annual mean indirect loss of 1.1 million JPY (45.3 thousand USD) per person. Higher WPAI (impairment) was associated with being male, moderate-to-severe disease severity, and low treatment adherence (P< 0.05). Biologics/JAKi users had higher work impairment, and IM/IS users had higher activity impairment than 5-aminosalicylic acid users (P< 0.05).
Conclusions
Despite treatment, Japanese UC patients experienced high disease burden and persistent disease-related challenges. Overall HRQoL were lower than the mean healthy population and work productivity impairment led to high indirect costs. The findings suggest the importance of new interventions for optimizing UC outcomes.

Citations

Citations to this article as recorded by

Selective Drug‐Free Active Surveillance in Ulcerative Colitis: Biomarker‐Guided, Patient‐Centered Approach
Tsutomu Nishida, Naoto Osugi, Takahiro Amano, Takeo Yoshihara
JGH Open.2026;[Epub] CrossRef
Therapeutic Impact on Quality of Life in Adult Patients With Chronic Intestinal Pseudo-obstruction: A Multicenter, Cohort Study
Kota Takahashi, Takaomi Kessoku, Hidenori Ohkubo, Yo Ishihara, Kosuke Tanaka, Tomoki Ogata, Tsumugi Jono, Atsushi Yamamoto, Anna Ozaki, Yuki Kasai, Michihiro Iwaki, Akiko Fuyuki, Takayuki Kato, Yasunari Sakamoto, Takeo Kurihashi, Hirotoshi Ebinuma, Atsush
Journal of Neurogastroenterology and Motility.2026; 32(2): 244. CrossRef
Towards an Asian paradigm of inflammatory bowel disease management: A comparative review of China and Japan
Qi Sun, Zhixian Jiang, Lichao Yang, Hao Liu, Peipei Song, Lianwen Yuan
Intractable & Rare Diseases Research.2025; 14(3): 192. CrossRef
Impact of Inflammatory Bowel Disease on Quality of Life and Work Productivity in Patients Under Treatment
Nikolaos Kafalis, Dionysios Kogias, Vasileios P Papadopoulos, Ioannis Moschos, Panagiotis Skendros, Konstantinos Ritis, Georgios Kouklakis
Cureus.2025;[Epub] CrossRef
Effectiveness of personalized physical rehabilitation within resort therapy for chronic non-infectious enteritis
Felix Filak, Yaroslav Filak, Yaroslav Mykhalko, Vitalina Ivachevska
Acta Balneologica.2025; : 459. CrossRef

9,592 View
389 Download
4 Web of Science
5 Crossref

First
Prev
Page of 1
Next
Last

Search